Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is -55.10% as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly return on assets; no daily interpolation.
Limited quarterly history available
ROA needs at least three reported quarters before a meaningful chart is shown.
RETURN ON ASSETS (ROA)
-55.10%
RETURN ON ASSETS (ROA) AVG TTM
N/A
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-70.91%
vs the sector median at left
Odyssey Therapeutics, Inc.
Market Cap
$870.81M
Return on Assets (ROA)
-55.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$867.03M
Return on Assets (ROA)
-5.88%
TTM Avg
-10.67%
3Y Avg
-19.76%
5Y Avg
-21.39%
Market Cap
$857.16M
Return on Assets (ROA)
-18.34%
TTM Avg
-25.78%
3Y Avg
-11.37%
5Y Avg
4.46%
Market Cap
$884.97M
Return on Assets (ROA)
55.85%
TTM Avg
-44.25%
3Y Avg
-43.62%
5Y Avg
-43.05%
Market Cap
$855.38M
Return on Assets (ROA)
-78.30%
TTM Avg
-72.68%
3Y Avg
-105.45%
5Y Avg
-105.45%
Market Cap
$887.50M
Return on Assets (ROA)
8.09%
TTM Avg
-0.64%
3Y Avg
-8.03%
5Y Avg
-4.54%
Market Cap
$887.99M
Return on Assets (ROA)
-22.62%
TTM Avg
-55.95%
3Y Avg
-57.94%
5Y Avg
-46.38%
Market Cap
$853.13M
Return on Assets (ROA)
61.78%
TTM Avg
41.06%
3Y Avg
4.27%
5Y Avg
-3.43%
Market Cap
$852.35M
Return on Assets (ROA)
-135.59%
TTM Avg
-77.84%
3Y Avg
-48.75%
5Y Avg
-48.75%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $870.81M | -55.10% | N/A | N/A | N/A |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | -5.88% | -10.67% | -19.76% | -21.39% |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | -18.34% | -25.78% | -11.37% | 4.46% |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | 55.85% | -44.25% | -43.62% | -43.05% |
| Alumis Inc. (ALMS)vs › | $855.38M | -78.30% | -72.68% | -105.45% | -105.45% |
| Bioventus Inc. (BVS)vs › | $887.50M | 8.09% | -0.64% | -8.03% | -4.54% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | -22.62% | -55.95% | -57.94% | -46.38% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 61.78% | 41.06% | 4.27% | -3.43% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | -135.59% | -77.84% | -48.75% | -48.75% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | -17.48% | -47.13% | -32.40% | -21.92% |
ROA
-55.1%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -55.10% |
